Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology

Finding the Cause: Genetic Testing and Major Subtypes

At a Glance

Genetic testing is the only way to confirm an Autosomal Recessive Cerebellar Ataxia (ARCA) subtype. Pinpointing your exact gene mutation guides proper treatment, rules out vitamin-responsive mimics like AVED, and alerts doctors to monitor your heart or immune system.

The path to an Autosomal Recessive Cerebellar Ataxia (ARCA) diagnosis is often a transition from clinical observation—noticing how you move and balance—to molecular confirmation through your DNA [1][2]. Because symptoms of different ataxias overlap so much, finding the specific genetic “instruction error” is the only way to know exactly which subtype you have and what care you need [3].

The Diagnostic Tools

The search for an answer usually follows a step-by-step process. Doctors start with simple blood tests and move toward high-tech genetic scans.

  • Biomarkers (The “Early Clues”): Before doing expensive genetic tests, doctors check for “biomarkers”—substances in your blood that act like red flags.
    • Alpha-fetoprotein (AFP): This protein is a major clue. If it is elevated, it strongly points toward specific subtypes like Ataxia-Telangiectasia (A-T) or Ataxia Oculomotor Apraxia [4][5].
    • Vitamin E Levels: This is a critical test. If Vitamin E is very low, it may indicate a specific, highly treatable form of ataxia called AVED [3].
  • Targeted Genetic Testing: The most common form of ARCA is Friedreich’s Ataxia (FRDA). It is caused by a “repeat expansion” (a stutter in the DNA). Doctors usually order a specific targeted test just for the FXN gene first, because broader tests often miss this stutter [6][7].
  • Next-Generation Sequencing (NGS) & Whole Exome Sequencing (WES): If targeted tests are negative, doctors use WES. WES specifically looks at the exons—the regions of your DNA that code for proteins (the actual “instructions” of the gene) [8]. This is exactly why WES can miss FRDA, which is caused by a stutter in a non-coding region (an intron). However, for many other complex cases, WES catches the cause in more than 50% of patients [9][10].

A logistical note: Advanced genetic testing like WES is expensive and often requires insurance pre-authorization or assistance programs. Ask your clinic’s genetic counselor about financial navigation options.

Common Subtypes and Their Genes

Identifying your subtype is “mandatory” because it tells your doctor what to monitor beyond your balance—such as your heart, your eyes, or your immune system.

Subtype Gene Involved Key Identifying Features
Friedreich’s Ataxia (FRDA) FXN The most common ARCA; often involves heart issues (cardiomyopathy) and scoliosis [11][12].
Ataxia-Telangiectasia (A-T) ATM Includes involuntary movements (dystonia/chorea) and sometimes tiny red “spider veins” on the skin or eyes (telangiectasias) [13][14].
Ataxia with Vitamin E Deficiency (AVED) TTPA Looks very similar to FRDA but is uniquely treatable with high-dose Vitamin E [3][15].
SPG7-Related Ataxia SPG7 Often presents as a mix of ataxia and “spasticity” (stiff or tight muscles), and may involve bladder issues [16][17].
SYNE1-Related Ataxia SYNE1 Typically a slowly progressive form that may start later in adulthood compared to other recessive ataxias [18][19].

Why an Exact Diagnosis is Crucial

A “clinical diagnosis” (guessing based on symptoms) is no longer enough in modern medicine. Finding the exact gene mutation is necessary for several reasons:

  1. Rule out “Mimics”: Some ataxias are caused by vitamin deficiencies or autoimmune reactions that can be reversed if caught early [20].
  2. Targeted Monitoring: If you have FRDA, your doctor needs to monitor your heart [11]. If you have A-T, they need to monitor your immune system [13].
  3. Family Planning: Knowing your specific mutation allows other family members, guided by a Genetic Counselor, to understand their own carrier status or family planning risks [21].
  4. Clinical Trial Eligibility: Almost all new research requires proof of a specific genetic mutation to participate [22].

Next Step: Learn how these specific diagnoses change your care plan in Standard of Care: Treatments and Management Strategies.

Common questions in this guide

Why do I need a targeted genetic test for Friedreich's Ataxia?
Friedreich's Ataxia is caused by a DNA stutter in a non-coding region of the FXN gene. Broad genetic scans like Whole Exome Sequencing (WES) often miss this specific stutter, which is why doctors must order a targeted genetic test first.
What biomarkers are checked before genetic testing for ARCA?
Doctors often check your blood for Alpha-fetoprotein (AFP) and Vitamin E levels before ordering complex genetic scans. Elevated AFP points to specific subtypes like Ataxia-Telangiectasia, while low Vitamin E indicates a highly treatable form of ataxia called AVED.
Why is getting an exact genetic diagnosis for ataxia so important?
An exact diagnosis helps rule out treatable conditions and guides doctors on what specific organs to monitor. It also informs family planning and determines your eligibility for targeted clinical trials.
Can ataxia be treated with vitamins?
While most ataxias cannot be cured with vitamins, a specific subtype called Ataxia with Vitamin E Deficiency (AVED) is uniquely treatable. If diagnosed, high-dose Vitamin E therapy can be used to manage the condition.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have I been specifically tested for GAA repeat expansions in the FXN gene? (I understand this is often missed by standard Exome Sequencing).
  2. 2.Can we check my Vitamin E and Alpha-fetoprotein (AFP) levels to rule out subtypes that have specific treatments or risks?
  3. 3.If my Whole Exome Sequencing (WES) was negative, should we consider Whole Genome Sequencing (WGS) or a more specific gene panel?
  4. 4.What is the specific 'pathogenic variant' identified in my report, and how does it relate to the symptoms I am currently experiencing?
  5. 5.Are there any non-neurological symptoms (like heart issues or immune system changes) associated with my specific subtype that we should be monitoring?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Molecular and clinical study of a cohort of 110 Algerian patients with autosomal recessive ataxia.

    Hamza W, Ali Pacha L, Hamadouche T, et al.

    BMC medical genetics 2015; (16()):36 doi:10.1186/s12881-015-0180-3.

    PMID: 26068213
  2. 2

    Autosomal-recessive cerebellar ataxias.

    Fogel BL

    Handbook of clinical neurology 2018; (147()):187-209 doi:10.1016/B978-0-444-63233-3.00013-0.

    PMID: 29325611
  3. 3

    Ataxia due to vitamin E deficiency: A case report and updated review.

    Thapa S, Shah S, Chand S, et al.

    Clinical case reports 2022; (10(9)):e6303 doi:10.1002/ccr3.6303.

    PMID: 36093469
  4. 4

    Autosomal Recessive Cerebellar Ataxias With Elevated Alpha-Fetoprotein: Uncommon Diseases, Common Biomarker.

    Renaud M, Tranchant C, Koenig M, Anheim M

    Movement disorders : official journal of the Movement Disorder Society 2020; (35(12)):2139-2149 doi:10.1002/mds.28307.

    PMID: 33044027
  5. 5

    Progressive Ataxia with Elevated Alpha-Fetoprotein: Diagnostic Issues and Review of the Literature.

    Paucar M, Taylor AMR, Hadjivassiliou M, et al.

    Tremor and other hyperkinetic movements (New York, N.Y.) 2019; (9()) doi:10.7916/tohm.v0.708.

    PMID: 31656689
  6. 6

    Generation of Friedreich's ataxia induced pluripotent stem cells carrying the FXN c.165 + 5G>C splicing mutation.

    Yameogo P, Gerhart BJ, Sentmanat MF, et al.

    Stem cell research 2026; (93()):103966 doi:10.1016/j.scr.2026.103966.

    PMID: 41865460
  7. 7

    The Impact of Next-Generation Sequencing on the Diagnosis, Treatment, and Prevention of Hereditary Neuromuscular Disorders.

    Beecroft SJ, Lamont PJ, Edwards S, et al.

    Molecular diagnosis & therapy 2020; (24(6)):641-652 doi:10.1007/s40291-020-00495-2.

    PMID: 32997275
  8. 8

    Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability: A systematic review and meta-analysis.

    Stefanski A, Calle-López Y, Leu C, et al.

    Epilepsia 2021; (62(1)):143-151 doi:10.1111/epi.16755.

    PMID: 33200402
  9. 9

    Genetic spectrum and clinical features in a cohort of Chinese patients with autosomal recessive cerebellar ataxias.

    Cheng HL, Shao YR, Dong Y, et al.

    Translational neurodegeneration 2021; (10(1)):40 doi:10.1186/s40035-021-00264-z.

    PMID: 34663476
  10. 10

    A study in a Polish ataxia cohort indicates genetic heterogeneity and points to MTCL1 as a novel candidate gene.

    Krygier M, Kwarciany M, Wasilewska K, et al.

    Clinical genetics 2019; (95(3)):415-419 doi:10.1111/cge.13489.

    PMID: 30548255
  11. 11

    Neuro-Ophthalmological Findings in Friedreich's Ataxia.

    Rojas P, de Hoz R, Cadena M, et al.

    Journal of personalized medicine 2021; (11(8)) doi:10.3390/jpm11080708.

    PMID: 34442352
  12. 12

    Frataxin deficiency alters gene expression in Friedreich ataxia derived IPSC-neurons and cardiomyocytes.

    Angulo MB, Bertalovitz A, Argenziano MA, et al.

    Molecular genetics & genomic medicine 2023; (11(1)):e2093 doi:10.1002/mgg3.2093.

    PMID: 36369844
  13. 13

    More Than Ataxia: Hyperkinetic Movement Disorders in Childhood Autosomal Recessive Ataxia Syndromes.

    Pearson TS

    Tremor and other hyperkinetic movements (New York, N.Y.) 2016; (6()):368 doi:10.7916/D8H70FSS.

    PMID: 27536460
  14. 14

    Clinical and genetic analysis of a case series of 12 Chinese families with hereditary ataxia.

    Guo L, Wu F, Wang Y, et al.

    Frontiers in neurology 2025; (16()):1595505 doi:10.3389/fneur.2025.1595505.

    PMID: 40635703
  15. 15

    Ataxia with vitamin e deficiency in norway.

    Elkamil A, Johansen KK, Aasly J

    Journal of movement disorders 2015; (8(1)):33-6 doi:10.14802/jmd.14030.

    PMID: 25614784
  16. 16

    A founder mutation p.H701P identified as a major cause of SPG7 in Norway.

    Rydning SL, Wedding IM, Koht J, et al.

    European journal of neurology 2016; (23(4)):763-71 doi:10.1111/ene.12937.

    PMID: 26756429
  17. 17

    Spastic ataxias.

    Bereznyakova O, Dupré N

    Handbook of clinical neurology 2018; (155()):191-203 doi:10.1016/B978-0-444-64189-2.00012-3.

    PMID: 29891058
  18. 18

    Autosomal Recessive Cerebellar Ataxia 1: First Case Report Depicting a Variant in SYNE1 Gene in a Chilean Patient.

    Valentina Castillo J, Catherine Díaz S, Bustamante ML, et al.

    Cerebellum (London, England) 2021; (20(6)):938-941 doi:10.1007/s12311-021-01250-x.

    PMID: 33651373
  19. 19

    Recessive ataxias.

    Synofzik M, Németh AH

    Handbook of clinical neurology 2018; (155()):73-89 doi:10.1016/B978-0-444-64189-2.00005-6.

    PMID: 29891078
  20. 20

    Degenerative and acquired sporadic adult onset ataxia.

    Lieto M, Roca A, Santorelli FM, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2019; (40(7)):1335-1342 doi:10.1007/s10072-019-03856-w.

    PMID: 30927137
  21. 21

    Clinical Features and Molecular Genetics of Autosomal Recessive Ataxia in the Turkish Population.

    Incecik F, Herguner OM, Mungan NO

    Journal of pediatric neurosciences 2020; (15(2)):86-89 doi:10.4103/jpn.JPN_145_18.

    PMID: 33042236
  22. 22

    The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias.

    Traschütz A, Reich S, Adarmes AD, et al.

    Frontiers in neurology 2021; (12()):677551 doi:10.3389/fneur.2021.677551.

    PMID: 34248822

This page explains genetic testing and subtypes of autosomal recessive cerebellar ataxia (ARCA) for educational purposes. Always consult a genetic counselor or neurologist to discuss testing options and interpret your genetic reports.

Get notified when new evidence is published on Autosomal recessive cerebellar ataxia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.